The ARL15 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal population generated from the A-549 human lung adenocarcinoma epithelial cell line, engineered to ablate expression of the ARL15 GTPase. Unlike clonal knockout cell lines, this polyclonal product retains a heterogeneous mixture of editing alleles, minimizing clonal artifacts and providing a more representative model of gene function disruption in a population context. The cells are suitable for biochemical, imaging, and functional assays that do not require isogenic homogeneity.
A-549 cells are a well-characterized adherent epithelial line derived from a 58-year-old male with lung adenocarcinoma. They exhibit features of alveolar type II pneumocytes, including the presence of lamellar bodies and surfactant protein expression, and are extensively used to study epithelial cell biology, signal transduction, and drug transport in the lung. Their robust growth kinetics and susceptibility to standard transfection and lentiviral transduction protocols make them a versatile host for genome engineering.
ARL15 encodes an ADP-ribosylation factor-like small GTPase that governs cargo sorting and vesicle formation at the endoplasmic reticulum?CGolgi interface. Under stimulation by upstream regulatory cues such as insulin, PPARG, and cAMP, ARL15 cycles between GDP- and GTP-bound conformations, promoting the assembly of COPII-coated vesicles that transport adiponectin (ADIPOQ) to the plasma membrane for secretion. Interacting proteins include ARF GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs), which regulate ARL15 nucleotide state, and COPII coat components that mediate vesicle budding. Once secreted, ADIPOQ activates the insulin receptor (INSR) and downstream IRS1?CAKT signaling cascade, ultimately promoting GLUT4 translocation and glucose uptake. Therefore, ARL15 occupies a critical node linking intracellular trafficking to systemic insulin sensitivity.
In the A-549 cellular context, CRISPR/Cas9-mediated knockout of ARL15 leads to defective ADIPOQ-containing vesicle trafficking and diminished adipokine release, thereby uncoupling extracellular adiponectin signaling from its intracellular effectors. This disruption attenuates insulin-stimulated AKT phosphorylation and GLUT4 plasma membrane translocation, recapitulating hallmark features of insulin resistance. The A-549 ARL15 knockout polyclonal population thus serves as a tractable epithelial model for investigating the cell-autonomous defects that contribute to metabolic syndrome, obesity, and type 2 diabetes, without the confounding influence of mesenchymal or other tissue-specific factors.
This cell product is suited for a range of experimental approaches, including adiponectin ELISA, Western blot analysis of ARL15 and phosphorylated AKT, RT-qPCR for ADIPOQ and GLUT4 transcripts, and immunofluorescence visualization of COPII vesicle components. Functional assays such as insulin-stimulated glucose uptake and phospho-AKT (Ser473) quantification enable signaling pathway dissection. The polyclonal knockout format is valuable for population-based studies, including drug screening for insulin-sensitizing compounds and investigations into metabolic reprogramming in cancer cells. For additional product information, please contact Ascent Research.
